This article has Open Peer Review reports available.
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
- Patricia M. LoRusso1Email author,
- Jeffrey R. Infante2, 3,
- Kevin B. Kim4,
- Howard A. BurrisIII2, 3,
- Gregory Curt^5,
- Ugochi Emeribe5,
- Delyth Clemett6,
- Helen K. Tomkinson6 and
- Roger B. Cohen7
© The Author(s). 2017
Received: 19 August 2016
Accepted: 15 February 2017
Published: 6 March 2017
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|19 Aug 2016||Submitted||Original manuscript|
|30 Aug 2016||Author responded||Author comments - Patricia M LoRusso|
|Resubmission - Version 2|
|30 Aug 2016||Submitted||Manuscript version 2|
|23 Sep 2016||Reviewed||Reviewer Report - Roberto Passera|
|23 Sep 2016||Reviewed||Reviewer Report - Nagio Takigawa|
|21 Dec 2016||Author responded||Author comments - Patricia M LoRusso|
|Resubmission - Version 3|
|21 Dec 2016||Submitted||Manuscript version 3|
|12 Jan 2017||Author responded||Author comments - Patricia M LoRusso|
|Resubmission - Version 4|
|12 Jan 2017||Submitted||Manuscript version 4|
|15 Feb 2017||Editorially accepted|
|6 Mar 2017||Article published||10.1186/s12885-017-3143-6|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.